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http://dx.doi.org/10.1016/j.jmii.2012Background: Enteropathogenic Escherichia coli (EPEC) is an important cause of diarrhea in
human. This study was conducted to investigate the ability of orally administrated probiotic
lactobacilli to protect hosts from EPEC infection via enhancement of immune responses.
Methods: Lyophilized Lactobacillus gasseri TMC0356 (TMC0356) was orally administered to
Institute of Cancer Research (ICR) mice and Sprague Dawley (SD) rats for 11 and 7 days, respec-
tively. These tested mice and rats were intraperitoneally injected with EPEC. Body weight,
general symptoms (piloerection, soft stool, diarrhea, and anal hyperemia), and mortality of
the tested mice were observed. Peritoneal macrophages were extracted from peritoneal
cavity of tested rats, and their phagocytosis and cytokine production were analyzed.
Results: Oral administration of TMC0356 accelerated the disappearance of general symptoms
and reduced mortality of EPEC-infected mice in the early phase. Peritoneal macrophages from
rats orally administered with TMC0356 showed significant increases in phagocytic activity
(p < 0.05) and interleukin (IL)-6 production (p < 0.01) compared to those from control rats.
Tumor necrosis factor-a and production of IL-1b, IL-10, and IL-12 slightly increased, although
the changes were not statistically significant.
Conclusion: These results suggest that some of selected probiotic lactobacilli may, at least
partly, protect hosts from EPEC infection by the enhancement of innate immunity of host
and attenuate symptoms caused by the infection.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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82 K. Yoda et al.IntroductionEnteropathogenic Escherichia coli (EPEC) infection
frequently leads to serious disorders such as diarrhea,
fever, or death, especially in children and aged persons.
Current measures to control the infection rely on the
intensive use of antibiotics. However, excessive use of
antibiotics has become a major problem because it
produces antibiotic-resistant bacteria.1 In fact, many
studies have reported the isolation of antibiotic-resistant
EPEC strains from humans.2,3 In addition, the use of anti-
bacterial agents is often associated with a range of adverse
effects, from fever and nausea to major allergic reactions
including photodermatitis.4 For these reasons, alternative
therapeutic strategies without antibiotics for entero-
pathogenic infection should be established.
Probiotics are defined as live microorganisms that confer
health benefits to the host when administered in adequate
amounts.5 Colonization, even temporary, of live cells in the
host intestine after oral administration of probiotics is
generally considered to be one of the important underlying
mechanisms by which probiotics such as lactobacilli and bifi-
dobacteria improve intestinal microbiota and enhance the
natural defense of host animals against various infections.6,7
In several animal studies, some probiotic lactobacilli have
shown apparent protective effects against enteropathogens
such as Salmonella typhimurium, E. coli, Shigella sonnei, and
Listeria monocytogenes.8e10 Therefore, probiotics have been
suggested as potent alternatives to antibiotic agents. Mecha-
nisms proposed to account for the protective effects in animal
studies include stabilization of the gut mucosal barrier,11
competition for nutrients, secretion of antimicrobial
substances (bacteriocins), andmodulation of themucosal and
systemic immune responses.12 Increasing evidence shows that
these protective effects are not genus or species specific, but
strain specific.12,13 Accordingly, additional knowledge about
strain-dependent functions and related underlying mecha-
nisms of each probiotics may promote the appropriate use of
these helpful bacteria as alternative drugs.
This study was conducted to evaluate the potential
protective effects of orally administered Lactobacillus
gasseri TMC0356 on EPEC infection using both a mouse and
a rat model.Materials and methods
Bacteria
L. gasseri TMC0356 (Takanashi Milk Products Co., Ltd,
Yokohama, Japan) was routinely cultured at 37C for 18
hours in de Man-Rogosa-Sharp broth (Becton, Dickinson,
Sparks, MD, USA). After incubation, cultured bacteria
collected by centrifugation were washed three times with
sterilized saline and lyophilized.
EPEC Juhl strain (supplied by Mercian Corporation,
Tokyo, Japan) was grown at 37C, with shaking in glucose
phosphate peptone medium until the mid-exponential
phase (absorbance at 660 nm, 1.0), and then diluted with
sterilized saline to the viable cell count appropriate for
each experiment.Animal experiments
Male 3-week-old ICR mice and 5-week-old SD rats were
purchased from Japan SLC, Inc. (Shizuoka, Japan) and
housed at 24  3C and 55  15% relative humidity with
a 12-hour lightedark cycle. The animals were fed a standard
diet (MF diet, Oriental Yeast, Tokyo, Japan). All experi-
ments were performed in accordance with the laboratory-
animal care guidelines of Mercian Cleantec Co., Ltd
(Kanagawa, Japan) and Takanashi Milk Products Co., Ltd.
The mice were divided into three groupsdcontrol,
E. coli, and TMC0356. Lyophilized lactobacilli were orally
administered to TMC0356 group mice at a dose of 10 mg/
d for 11 days prior to E. coli infection and for 1 day after the
infection. The other mice were given saline solution orally
during the same periods. After 11 days of the experiment,
2  107 or 7.5  107 cells of E. coli were intraperitoneally
injected into all test mice except the control mice. Body
weight of all mice was measured, and general symptoms
(piloerection, soft stool, diarrhea, and anal hyperemia) and
mortality were also observed.
The rats were divided into two groupsdcontrol and
TMC0356dand intraperitoneally injected with 2  107 cells
of E. coli on Day 7 of the experiment. TMC0356 group rats
were gavaged with 100 mg of the test bacteria each day
throughout the experimental period. Control rats were
given saline solution orally during the same period. Two
days after infection, rats were sacrificed by exsanguination
to obtain peritoneal macrophages without blood contami-
nation. Peritoneal cells were extracted from the peritoneal
cavity with 20 mL of ice-cold sterile phosphate-buffered
saline (PBS). The extracted cells suspended in RPMI1640
media containing 10% fetal bovine serum (FBS) were plated
onto eight-well chamber slides (2  105 cells/well) or 24-
well culture plates (2  106 cells/well), and incubated at
37C for 1 hour in a 5% CO2 chamber. After washing by the
same media to remove nonadherent cells, the adherent
cells were used as peritoneal macrophages.
Macrophage phagocytosis assay
For the phagocytosis assay, latex beads (1.1 mm, Sigmae
Aldrich, St Louis, MO, USA) suspended at a concentration of
0.02% in RPMI1640 containing 10% FBS were added to each
chamber slide well and incubated with the macrophages at
37C for 15 minutes. After incubation, the cultures were
washed twicewithPBS, fixedwithmethanol, and stainedwith
Giemsa. A total of 300 macrophage cells per rat were coun-
ted, thenumberofmacrophagescontaining oneormore latex
beads was determined microscopically, and the percent of
phagocytic macrophage was defined as the phagocytic rate.
Measurements of cytokines from peritoneal
macrophages
Peritoneal macrophages cultured on the 24-well plate were
incubated in 900 mL of RPMI1640 containing 10% FBS with
100 mL of lipopolysaccharide (LPS, SigmaeAldrich) suspen-
sion (10 mg/mL in PBS) or PBS, at 37C for 24 hours, to
stimulate cytokine production. Concentrations of inter-
leukin (IL)-1b, IL-6, IL-12, and tumor necrosis factor (TNF)-
Probiotic lactobacilli against E. coli infection 83a in the culture supernatant were determined using the
sandwich enzyme-linked immunosorbent assay (ELISA)
method.
Statistical analysis
The results were expressed as means  standard error of
the mean (SEM). Statistical comparisons between three
groups were made using the TukeyeKramer test. Differ-
ences in the survival rate were examined by KaplaneMeier
method followed by a log-rank test. Comparisons between
two groups were calculated by Student t test. A p value of
<0.05 was considered statistically significant.
Results
When 2  107 cells of enteropathogenic E. coli Juhl were
injected into mice, all the mice survived until the end of the
experiment (data not shown). The average body weights of
the three groups were not significantly different until the day
of infection (Day 0: body weight of control, 33.0  0.9 g;
E. coli, 33.9 0.7 g; andTMC0356, 33.3 0.8 g); however, the
body weight of TMC0356 group mice decreased significantly
after infection compared to that of control mice (Fig. 1A).
E. coli group mice did not show any significant differences in
average body weight compared with the other group miceA
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Figure 1. Effects of oral administration of TMC0356 on body weig
pathogenic E. coli Juhl. In mice infected with 2  107 cells of E. coli
(open squares: control group; open triangles: E. coli group; closed
symptoms including piloerection, soft stool, diarrhea, and anal hyp
group; closed circles: E. coli group; open squares: TMC0356 group)
(A) are expressed as means  SEM for each group. *p < 0.05 compa
error of the mean.during the experimental period except at Day 2. General
symptoms including piloerection, soft stool, and diarrhea
were observed in most of the infected mice for 2 days after
infection (Fig. 1B). The proportion of mice exhibiting these
symptomsdeclined rapidly in theTMC0356groupcompared to
that in the E. coli group during the next 5 days. Irrespective of
whether or not TMC0356 was orally administered, the final
survival rate of mice infected with 7.5  107 cells of E. coli
dropped to 30% (Fig. 1C).
Phagocytic activity of peritoneal macrophages isolated
from infected rats was measured as phagocytic rate
(Fig. 2). Oral administration of TMC0356 significantly raised
the phagocytic rate in the infected rats.
Concentrations of TNF-a, IL-10, IL-6, IL-1b, and IL-12 in
macrophage culture supernatant were measured (Fig. 3).
Macrophages isolated from TMC0356 group rats secreted
more IL-6 than those from E. coli group rats without LPS
stimulation (p < 0.01). However, no significant differences
between E. coli and TMC0356 group rats were observed in
the production of other cytokines regardless of whether
macrophages were stimulated with LPS or not.
Discussion
TMC0356 is a probiotic strain originally isolated from
a human intestine.14 This bacterium as well as its inactive0%
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ht, general symptoms, and survival rate in mice challenged with
, transition of body weight during the total experimental period
circles: TMC0356 group) (A) and rate of mice exhibiting general
eremia after infection (B). Survival rate (open circles: control
of mice challenged with 7.5  107 cells of E. coli (C). Results of
red with control; nZ 10 in each group (AeC). SEMZ standard
Figure 2. Phagocytic rate of peritoneal macrophages in rats
infected with pathogenic E. coli. TMC0356 was orally admin-
istered to rats for 8 days prior to the infection. After 2 days of
the challenge (Day 10), peritoneal macrophages were obtained
from the challenged rats to measure the phagocytic activity.
Results are expressed as mean  SEM (E. coli group, n Z 8;
TMC0356 group, n Z 7). *Significant difference from E. coli
group at p < 0.05. SEM Z standard error of the mean.
Figure 3. Cytokine production by peritoneal macrophage deriv
macrophage obtained from infected rats in each group (E. coli grou
of LPS, LPS (e), or presence of LPS, LPS (þ). Concentrations of TNF-
were determined by the sandwich ELISA method. Results are expre
at p < 0.01. SEM Z standard error of the mean.
84 K. Yoda et al.cells can activate macrophages in a strain-dependent
manner to induce the production of inflammatory and
anti-inflammatory cytokines,15,16 improve age-associated
immune cell-mediated senescence,17 protect mice from
influenza infection,18e20 and alleviate allergic disor-
ders.21,22 These results lead to a hypothesis that TMC0356
may protect a host from enteropathogenic infection
through its characteristic immune-stimulatory effect,
although it does not secrete any antimicrobial agent as do
other strains used as probiotics.
In the present study, orally administrated TMC0356
accelerated the disappearance of general symptoms such
as piloerection, soft stool, and diarrhea, in mice injected
with a low dose of EPEC. The survival rate of TMC0356 group
mice challenged with high enteropathogenic bacterial
numbers was also elevated for 3 days after infection,
although there was no difference between TMC0356 and E.
coli group mice eventually. These results suggested that
TMC0356 may confer protective effects against a mild
degree of EPEC infection and attenuate symptoms caused
by the infection, especially in the early phase.
Kubota et al reported that oral administration of fer-
mented milk containing Lactobacillus rhamnosus GG and
TMC0356 stabilized intestinal microbiota and might
increase bifidobacteria in patients with Japanese cedar
pollinosis.21,22 Furthermore, the ingested TMC0356 was
demonstrated, using strain-specific detection by pulsed-
field gel electrophoresis, to survive well and colonize in
the host intestine.23 Based on these results, orally admin-
istered TMC0356 was considered to have survived and
colonized in the intestine of the tested mice and rats at
least temporarily during the intervention of the present
study. Activation of TMC0356 in the intestines leading to
direct and indirect influence on the intestinal microbiotaed from rats challenged with pathogenic E. coli. Peritoneal
p, nZ 8; TMC0356 group, nZ 7) were cultured in the absence
a, IL-10, IL-6, IL-1b, and IL-12 after 24 hours in the supernatant
ssed as mean  SEM. **Significant difference from E. coli group
Probiotic lactobacilli against E. coli infection 85may be one part of the underlying mechanism behind the
preventive effects of TMC0356 on general symptoms caused
by EPEC infection. Interestingly, the present study is the
first report indicating that TMC0356 administrated alone
alleviate defecation problems of host animals, although
this was not the main objective of this study.
Macrophages are known as key players of the innate
immune system, eliminating pathogens by their phagocytic
activity. Contact of macrophages with pathogens provokes
the expression of proinflammatory cytokines and mediators
that orchestrate pathogen killing and further coordinate
the immune response. The present study showed that
phagocytic activity of peritoneal macrophage obtained
from rats after 2 days of EPEC challenge was markedly
enhanced in the TMC0356 group compared to that in the
control group. These results suggest that the preventive
effects of TMC0356 on EPEC infection may result from the
enhancement of the innate immunity of the host by this
bacterium, partially with activation of peritoneal
macrophages.
In the present study, IL-6 production from isolated
macrophages was significantly increased, whereas it was
apparently unchanged in the presence of LPS stimulation.
These results were in agreement with a previous study in
which TMC0356 stimulated the proliferation of mouse
spleen cells but did not amplify the proliferation stimulated
by mitogens such as concanavalin A.24 These results are also
in good agreements with the previous observation that the
immune-stimulatory effects of TMC0356 were mild and
different from those of a pathogenic agent such as E. coli
(data not shown). The mild immune-regulatory effect of
TMC0356 may limit the protective effects of this bacterium.
However, this characterized immune-regulatory effect of
TMC0356 might support the safety of this bacterium for use
as a probiotic in human foods.
It is known that a low concentration of IL-6 induces the
production of secretory immunoglobulin A (IgA), which is an
important factor to protect hosts from pathogens at the
mucosal level.25 However, Harata et al reported that
intragastrically administered TMC0356 did not enhance
total IgA production by Peyer’s patch cells in mice, even
though it induced IgA production from isolated murine
Peyer’s patch cells cocultured with TMC0356 in vitro.26
Therefore, further work is needed to measure total IgA
level in a rat model. Based on these findings, the mecha-
nism of the protective effects of TMC0356 administration
on pathogen infection may largely be because of the
phagocytic activity of macrophages themselves, and not
because of the adaptive immunity, involving the production
of Th1-cytokines (IL-12 and TNF-a) in macrophages, or
humoral immunity. In any case, further work should be
conducted to clarify if the actions of TMC0356 on host
immunity may be host specific, and know if this bacterium
originating from human may behave differently in murine
models.
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